TY - JOUR T1 - Does heliox administered by low-flow nasal cannula improve respiratory distress in infants with respiratory syncytial virus acute bronchiolitis? A randomised controlled trial JO - Anales de PediatrĂ­a (English Edition) T2 - AU - Seliem,Wael AU - Sultan,Amira M. SN - 23412879 M3 - 10.1016/j.anpede.2018.03.003 DO - 10.1016/j.anpede.2018.03.003 UR - https://www.analesdepediatria.org/en-does-heliox-administered-by-low-flow-articulo-S2341287918300577 AB - ObjectivesThe aim of our study is to evaluate whether the use of heliox (79:21) delivered through a low flow nasal cannula would improve respiratory distress in infants with acute bronchiolitis caused by RSV. MethodsWe have conducted a prospective randomised controlled study. All patients fulfilling inclusion criteria were randomised to either heliox (79:21) or air via NC at 2L/min for a continuous 24h. Measurements were taken at baseline, after 2h and at the end of the 24h. ResultsWe have included 104 patients into our study. The MCA-S did not show any significant difference between the two groups after 2h 4.3 vs. 4.1 (P=.78), or at 24h after 4.2 vs. 4.3 (P=.89). No difference was found in the proportion of participants progressed to MV, n-CPAP or oxygen via nasal cannula (RR 1.0, 0.86 and 0.89) (P=1.0, .77 and .73). There was no notable reduction in length of treatment in Heliox group 2.42 days vs. 2.79 days in air group P=.65. The oxygen saturation, PaO2, and PaCO2 did not have any statistical difference between the two studied groups after 2h and 24h of treatment. ConclusionOur data showed absence of any beneficial effect of heliox in a concentration (79:21) delivered through low flow nasal cannula in terms of respiratory distress improvement in infants with RSV acute bronchiolitis. ER -